Changchun Zhuanzhi Pharmaceutical

Changchun Zhuanzhi Pharmaceutical is a Chinese pharmaceutical company and a wholly-owned subsidiary of Changchun High-Tech Industries (Group) Inc. Established in 2020 and based in Changchun, Jilin Province, the company serves as a key manufacturing and development hub for high-end pharmaceutical preparations. Its primary focus is on metabolic diseases, specifically the production of peptide-based therapeutics such as GLP-1 receptor agonists. The company's portfolio includes the commercial-stage production of liraglutide and the development of semaglutide for indications including type 2 diabetes and obesity. Changchun Zhuanzhi operates state-of-the-art facilities designed to meet international GMP standards, supporting the parent group's expansion into the global metabolic health market.